QIAGEN Launches Assay Technology for miRNA Targets
Product News May 09, 2007
QIAGEN N.V. has introduced a technology which can create a new dimension of capabilities for assays targeting microRNAs (miRNAs).
miRNAs are a newly discovered class of RNA molecules which have been found to play a significant role in the regulation of gene expression.
QIAGEN unveiled a solution which allows for the sensitive, specific and simultaneous detection and quantification of hundreds of different miRNAs as well as other RNAs.
The miScript product line incorporates a technology which can enable researchers to identify multiple miRNAs from one single cDNA reaction in a given biological sample. cDNA is a synthesized copy of the RNA which is widely used for PCR-based target detection in molecular biology, biomedical and pharmaceutical research.
The features offered by QIAGEN's proprietary miScript assay technology can equate to substantial time savings while allowing sensitivity and specificity.
"The new miRNA system marks a great step forward in miRNA research", said Dr. Constanze Kindler, Senior Product Manager at QIAGEN.
"So far, researchers had to create a new copy of the DNA every time they wanted to detect a miRNA molecule. This often leads to inconsistent results and a waste of precious samples, such as cancer and tissue cells. miScript simply makes miRNA detection faster, more economical and convenient", Dr. Kindler added.
The system expands QIAGEN's portfolio of sample and assay technologies targeting the expanding field of miRNA and demonstrates the company's well established capabilities and leadership in the field of sample and assay technologies.
Together with QIAGEN's other sample and assay technologies products for miRNA such as with QIAGEN's miRNeasy kits, the QIAGEN miScript system forms an integrated and comprehensive solution for the isolation and detection of miRNAs in hundreds of assays, which are available for the human, mouse and rat genome.